← SynDRA
ASCIMINIB
SynDRA canonical compound SYN0039325 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ABL1 | BCR |
|---|
| Mechanism of action | Bcr-Abl kinase inhibitor |
|---|
All known targets
- ABL1
- BCR
- BCR-ABL1
- DLL4
- KCNH2
Mechanisms of action (all sources)
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- Bcr-Abl kinase inhibitor
- Inhibitor
- DLL4 INHIBITOR
Drug classes
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- asciminib hydrochloride
- scemblix
- ABL-001
- ABL-001-NX
- ABL001-AAA
- ABL-0013-PYRIDINECARBOXAMIDE
- ABL001
- ABL001-NX
- ASCIMINIB (ABL001)
- AY7
- N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXY-1-PYRROLIDINYL]-5-(1H-PYRAZOL-3-YL)-
- NVP-ABL001
- NOV1501
- TR009
- Asciminib free base
- UNII-L1F3R18W77
- L1F3R18W77
- (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide
- 1492952-76-7 (free base)
- N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
- Asciminib [USAN]
- Asciminib (ABL001)
- Asciminib (USAN/INN)
- GTPL8962
- CHEMBL4208229
- SCHEMBL15388306
- TQP0925
- EX-A3030
- BDBM50459091
- NSC789925
- s8555
- ZINC150275965
- CCG-269232
- CS-7655
- DB12597
- NSC-789925
- SB18878
- BS-15538
Reported adverse events
- Abdominal pain
- Fatigue
- Headache
- Hypersensitivity
- Hypertension
- Infection
- Musculoskeletal pain
- Myelosuppression
- Rash
- Upper respiratory tract infection
- Alanine aminotransferase
- Amylase
Look up ASCIMINIB in the interactive SynDRA portal →